Cargando…
Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy
Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024164/ https://www.ncbi.nlm.nih.gov/pubmed/31947577 http://dx.doi.org/10.3390/molecules25020333 |
_version_ | 1783498371601793024 |
---|---|
author | Nogueira, João Soares, Sofia F. Amorim, Carlos O. Amaral, João S. Silva, Cláudia Martel, Fátima Trindade, Tito Daniel-da-Silva, Ana L. |
author_facet | Nogueira, João Soares, Sofia F. Amorim, Carlos O. Amaral, João S. Silva, Cláudia Martel, Fátima Trindade, Tito Daniel-da-Silva, Ana L. |
author_sort | Nogueira, João |
collection | PubMed |
description | Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin. |
format | Online Article Text |
id | pubmed-7024164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70241642020-03-19 Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy Nogueira, João Soares, Sofia F. Amorim, Carlos O. Amaral, João S. Silva, Cláudia Martel, Fátima Trindade, Tito Daniel-da-Silva, Ana L. Molecules Article Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin. MDPI 2020-01-14 /pmc/articles/PMC7024164/ /pubmed/31947577 http://dx.doi.org/10.3390/molecules25020333 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nogueira, João Soares, Sofia F. Amorim, Carlos O. Amaral, João S. Silva, Cláudia Martel, Fátima Trindade, Tito Daniel-da-Silva, Ana L. Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title | Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title_full | Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title_fullStr | Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title_full_unstemmed | Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title_short | Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy |
title_sort | magnetic driven nanocarriers for ph-responsive doxorubicin release in cancer therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024164/ https://www.ncbi.nlm.nih.gov/pubmed/31947577 http://dx.doi.org/10.3390/molecules25020333 |
work_keys_str_mv | AT nogueirajoao magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT soaressofiaf magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT amorimcarloso magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT amaraljoaos magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT silvaclaudia magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT martelfatima magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT trindadetito magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy AT danieldasilvaanal magneticdrivennanocarriersforphresponsivedoxorubicinreleaseincancertherapy |